IRVINE, Calif., March 28, 2024 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. Fourth Quarter and Recent Highlights The… Continue reading Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
